Astellas Pharma Terminates $16/Sh Offer for CV Therapeutics (CVTX), Clearing Way For Gilead
Astellas Pharma Inc said it will terminate its $16.00 per share offer for CV Therapeutics, Inc. (Nasdaq: CVTX) and will not propose directors for the CV Therapeutics Board of Directors or make any other proposals at CV Therapeutics' 2009 annual meeting.
Late last week, CV Therapeutics agreed to be acquired by Gilead (Nasdaq: GILD) for $20 per share.
Late last week, CV Therapeutics agreed to be acquired by Gilead (Nasdaq: GILD) for $20 per share.
You May Also Be Interested In
- UPDATE: InterMune (ITMN) to Divest ActImmune for $55M in Cash, Plus Two-Year Royalty Stream
- Yucheng Technologies (YTEC) Gets Preliminary $3.30/Share 'Go Private' Offer from CEO
- SeaChange (SEAC) Sells On Demand Group to Avail-TVN in $27M Deal
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
